Krystal Biotech (KRYS) Net Cash Flow (2016 - 2026)

Krystal Biotech has reported Net Cash Flow for 11 years, with the latest figure at -$71.7 million in Q2 2026.

• Net Cash Flow for Q2 2026 came in at -$71.7 million, down 263.05% year-over-year; the trailing twelve-month figure through Jun 2026 was $78.0 million (up 995.59% YoY), and the FY2025 annual result was $151.2 million, up 1262.27% from the prior year.
• Net Cash Flow eased to -$71.7 million in Q2 2026, from $6.3 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $135.1 million in Q2 2023 and troughed at -$71.9 million in Q1 2022.
• A 5-year average of $5.0 million and a median of -$13.8 million in 2023 frame the typical range for Net Cash Flow.
• The largest YoY upside for Net Cash Flow was 466.0% in 2025 against a maximum downside of 7486.15% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$24.5 million in 2022, then surged by 39.62% to -$14.8 million in 2023, then plunged by 92.97% to -$28.5 million in 2024, then soared by 466.0% to $104.3 million in 2025, then plunged by 168.76% to -$71.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$71.7 million in Q2 2026, $6.3 million in Q1 2026, and $104.3 million in Q4 2025.